1 © 2025 Artivion, Inc. Corporate Overview May 2025 FORWARD-LOOKING STATEMENT These statements include our belief that we have driven and can continue to drive sustained double digit revenue growth and 2x+ EBIDTA Growth as a result of our highly differentiated highly defendable base business, our high growth stent graft business and our leverageable global infrastructure; our estimated total addressable markets for preservation services (human tissue), mechanical heart valves, and surgical sealants are $150 ...

Artivion (AORT) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Laine Morgan - Associate Vice PresidentPatrick Mackin - Chairman , President & CEOLance Berry - Executive VP & CFOJohn McAulay - AVPSuraj Kalia - Managing DirectorDaniel Stauder - Director - Equity ResearchJeffrey Cohen - MD - Equity Research Conference Call Participants Frank Takkinen - Senior Research AnalystMichael Matson - Senior Analyst Operator Greetings. Welcome to our Ativian's First Quarter twenty twenty five Financ ...

First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basis Net loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025 Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of ...